%PDF-1.7
%
1 0 obj
<>>>
endobj
2 0 obj
<>stream
2017-02-17T10:21:53-05:00
2017-02-17T10:21:54-05:00
2017-02-17T10:21:54-05:00
Adobe InDesign CC 2017 (Windows)
uuid:2b2a3d61-3c8b-4c60-9b38-e5acd6c7fb67
xmp.did:4A42F9656056E111960DCE8E95F0DF9D
xmp.id:c014df24-bac2-5645-a502-be6d5085e5cb
proof:pdf
xmp.iid:855d06af-55d0-ba48-a378-6405074f8b6b
xmp.did:f2895fc5-c509-9d4e-a07b-e79a0de9dca1
xmp.did:4A42F9656056E111960DCE8E95F0DF9D
default
converted
from application/x-indesign to application/pdf
Adobe InDesign CC 2017 (Windows)
/
2017-02-17T10:21:53-05:00
application/pdf
Adobe PDF Library 15.0
False
endstream
endobj
3 0 obj
<>
endobj
5 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
6 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text/ImageC/ImageI]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
16 0 obj
<>stream
BT
0 0 0 1 k
/GS0 gs
/TT0 1 Tf
7 0 0 7 60.48 22.6817 Tm
(2 )Tj
/Span<>> BDC
( )Tj
EMC
59.297 0 Td
[(Pharmacology W)54.6 (atch)]TJ
4.081 0 0 4.081 535.1605 25.0127 Tm
(\256)Tj
ET
q
0 g
/GS1 gs
0 TL/Fm0 Do
Q
BT
/T1_0 1 Tf
-0.01 Tc 7 0 0 7 40.75 257.75 Tm
(PHARMACOLOGY WATCH)Tj
/T1_1 1 Tf
6 0 0 6 127.892 257.75 Tm
[(\231 is published monthly by AHC Media, a Relias Learning)-10 ( )]TJ
-14.524 -1.167 Td
(company. Copyright \251 2017 AHC Media, a Relias Learning company.)Tj
/T1_2 1 Tf
0.01 Tw 8 0 0 8 40.75 240.75 Tm
(Author)Tj
/T1_1 1 Tf
(: )Tj
/T1_3 1 Tf
0 Tw 3.698 0 Td
(William T. Elliott, MD, FACP, )Tj
/T1_1 1 Tf
[(Assistant Clinical Professor of)-10 ( )]TJ
-3.698 -1.25 Td
(Medicine, University of California, San Francisco)Tj
/T1_2 1 Tf
0.01 Tw 0 -1.25 TD
(Editor:)Tj
/T1_1 1 Tf
0 Tw ( Jonathan Springston)Tj
/T1_2 1 Tf
T*
(Executive Editor:)Tj
/T1_1 1 Tf
( Leslie Coplin)Tj
6 0 0 6 40.75 199.25 Tm
[(This is an educational publication designed to present scientific inform\
ation and opinion to)-10 ( )]TJ
0 -1.167 TD
[(health professionals, stimulate thought, and further investigation. It d\
oes not provide advice)-10 ( )]TJ
0 -1.167 TD
[(regarding medical diagnosis or treatment for any individual case. It is \
not intended for the)-10 ( )]TJ
0.01 Tw 0 -1.167 TD
(layman.)Tj
0.01 Tc 0 Tw 0 -1.917 TD
(STATEMENT OF FINANCIAL DISCLOSURE)Tj
-0.01 Tc 0 -1.167 TD
[(To reveal any potential bias in this publication, and in accordance with\
Accreditation Council)-9.9 ( )]TJ
0 -1.167 TD
[(for Continuing Medical Education guidelines, Dr. Elliott, Ms. Coplin, an\
d Mr. Springston)-10 ( )]TJ
T*
(report no financial relationships relevant to this field of study.)Tj
ET
/CS0 CS 1 SCN
0.25 w 4 M
/GS1 gs
36.125 45.125 251.75 222.5 re
S
/CS0 cs 0.1 scn
122.4 50.76 160.85 69.12 re
f
0.86 0.57 0 0.16 K
0.3 w 10 M
q 1 0 0 1 167.2314 90.3042 cm
0 0 m
81.287 0 l
S
Q
q 1 0 0 1 151.4756 83.3042 cm
0 0 m
42.017 0 l
S
Q
BT
0 0 0 1 k
/GS0 gs
/T1_2 1 Tf
0.05 Tc 8 0 0 8 126.9 108.1801 Tm
[(SUBSCRIBER INFORMA)92 (TION)]TJ
-0.01 Tc 7 0 0 7 126.9 97.9041 Tm
(Customer Service: \(800\) 688-2421)Tj
/T1_1 1 Tf
6 0 0 6 126.9 90.9041 Tm
(Email Address: )Tj
0.86 0.57 0 0.16 k
/GS1 gs
0.01 Tw (jspringston@reliaslearning.com)Tj
0 0 0 1 k
/GS0 gs
T*
(Website: )Tj
0.86 0.57 0 0.16 k
/GS1 gs
4.096 0 Td
(AHCMedia.com)Tj
0 0 0 1 k
/GS0 gs
0 Tw -4.096 -1.917 Td
[(Address Correspondence to: AHC Media, a Relias)-10 ( )]TJ
T*
[(Learning company, 111 Corning Road, Suite 250, Cary,)-10 ( )]TJ
T*
(NC 27518)Tj
ET
q
50.538 73.418 59.014 32.443 re
W n
q
/GS1 gs
59.0137116 0 0 32.4424102 50.5378342 73.4188035 cm
/Im0 Do
Q
Q
BT
/T1_4 1 Tf
-0.03 Tc 10 0 0 10 36 736.2775 Tm
[(17% vs. 28% in study one, and 16% vs. 26% in study two)-30 ( )]TJ
0 Tc 0 -1.2 TD
(\()Tj
/T1_5 1 Tf
0.303 0 Td
(P)Tj
/T1_4 1 Tf
-0.03 Tc 0.581 0 Td
[( < 0.001 for both\). The rates of adverse events were similar)-29.9 ( )]TJ
-0.884 -1.2 Td
(across all groups. The addition of actoxumab to bezlotox)Tj
0 Tc (-)Tj
-0.03 Tc T*
[(umab did not improve ef\037cacy)92 (. The authors concluded that)-30 ( )]TJ
T*
[(bezlotoxumab was associated with a substantially lower rate)-30 ( )]TJ
T*
(of recurrent )Tj
/T1_5 1 Tf
(C. dif\037cile)Tj
/T1_4 1 Tf
[( infection compared to placebo with a)-29.9 ( )]TJ
T*
(good safety pro\037le \()Tj
/T1_5 1 Tf
(N Engl J Med)Tj
/T1_4 1 Tf
( 2017;376:305-317\).)Tj
/TT0 1 Tf
0 Tc 14 0 0 14 36 636.2775 Tm
[(Comparing First-line T)176 (reatments for )]TJ
14.754 0 Td
( )Tj
/TT1 1 Tf
-14.754 -1.143 Td
(C. Difficile)Tj
/TT0 1 Tf
3.988 0 Td
( Infections)Tj
/T1_4 1 Tf
-0.03 Tc 10 0 0 10 36 608.2775 Tm
[(In a related story)92 (, vancomycin and metronidazole are both)-30 ( )]TJ
T*
(used as \037rst-line treatment for )Tj
/T1_5 1 Tf
(C. dif\037cile)Tj
/T1_4 1 Tf
[( infections \(CDI\), but)-30 ( )]TJ
T*
[(vancomycin may be superior in reducing 30-day mortality)92 (, ac)]TJ
0 Tc (-)Tj
-0.03 Tc T*
[(cording to a new study)92 (. In a retrospective, propensity-matched)-30 ( )]TJ
T*
[(cohort study evaluating patients presenting with CDI from the)-30 ( )]TJ
T*
[(V)105 (A system, more than 47,000 patients \(96% men\) were evalu)]TJ
0 Tc (-)Tj
-0.03 Tc T*
[(ated. Initial treatment was 95.6% with metronidazole and)-30 ( )]TJ
T*
(4.4% vancomycin. The 2,068 vancomycin patients were case-)Tj
T*
[(matched with more than 8,000 metronidazole patients for the)-30 ( )]TJ
T*
[(evaluation. There was no difference in the risk of recurrence)-30 ( )]TJ
T*
[(between patients treated with vancomycin vs. those treated)-30 ( )]TJ
T*
[(with metronidazole. However)111 (, those treated with vancomycin)-30 ( )]TJ
T*
[(were less likely to die across all severity cohorts \(relative risk)-30 ( )]TJ
T*
[([RR], 0.86; 95% con\037dence interval [CI], 0.74-0.98\). No)-30 ( )]TJ
T*
[(difference in mortality was observed in patients with mild)-30 ( )]TJ
T*
(disease, but vancomycin signi\037cantly reduced the risk of all-)Tj
T*
[(cause, 30-day mortality in patients suffering from severe CDI)-29.9 ( )]TJ
T*
(\(adjusted RR, 0.79; 95% CI, 0.65-0.97; adjusted risk differ)Tj
0 Tc 23.794 0 Td
(-)Tj
-0.03 Tc -23.794 -1.2 Td
[(ence, -0.04; 95% CI, -0.007 to -0.01\). The authors concluded)-30 ( )]TJ
T*
[(that although the recurrence rates were similar among patients)-30 ( )]TJ
T*
(treated with vancomycin and metronidazole, the risk of 30-)Tj
T*
(day mortality was reduced in patients treated with vancomy)Tj
0 Tc (-)Tj
-0.03 Tc T*
[(cin, especially for those suffering from severe CDI. Although)-30 ( )]TJ
T*
[(metronidazole generally is recommended as \037rst-line therapy)92 (,)-30 ( )]TJ
T*
[(these \037ndings may justify use of vancomycin, especially in)-30 ( )]TJ
T*
(sicker patients \()Tj
/T1_5 1 Tf
(JAMA Intern Med)Tj
/T1_4 1 Tf
[(. Published online Feb. 6,)-30.1 ( )]TJ
T*
(2017. doi:10.1001/jamainternmed.2016.9045\).)Tj
/TT0 1 Tf
0 Tc 14 0 0 14 306 733.3608 Tm
[(P)17.6 (romising T)175.3 (reatment for Multiple Sclerosis )]TJ
0 -1.143 TD
(Closer to Approval)Tj
/T1_4 1 Tf
-0.03 Tc 10 0 0 10 306 705.3608 Tm
[(Ocrelizumab may be closer to approval for the treatment of)-30 ( )]TJ
0 -1.2 TD
[(progressive multiple sclerosis based on the recently published)-30 ( )]TJ
T*
(results of two studies. Ocrelizumab is a humanized mono)Tj
0 Tc (-)Tj
-0.03 Tc T*
[(clonal antibody that selectively depletes CD20-expressing B)-30 ( )]TJ
T*
[(cells. In the \037rst study)92 (, 732 patients with primary progressive)-30 ( )]TJ
T*
(multiple sclerosis were randomized 2:1 to receive intrave)Tj
0 Tc (-)Tj
-0.03 Tc T*
[(nous ocrelizumab or placebo every 24 weeks for at least 120)-30 ( )]TJ
T*
[(weeks and until a pre-speci\037ed number of con\037rmed disability)-30 ( )]TJ
T*
[(progression events occurred. The percentage of patients with)-30 ( )]TJ
T*
[(12-week con\037rmed disability progression \(primary endpoint\))-30 ( )]TJ
T*
[(was 32.9% with ocrelizumab vs. 39.3% with placebo \(hazard)-30 ( )]TJ
T*
(ratio [HR], 0.76; 95% CI, 0.59-0.98; )Tj
/T1_5 1 Tf
0 Tc (P)Tj
/T1_4 1 Tf
-0.03 Tc 15.866 0 Td
[( = 0.03\). At 24 weeks,)-30 ( )]TJ
-15.866 -1.2 Td
[(the percentages were 29.6% vs. 35.7%, respectively \(HR,)-30 ( )]TJ
T*
(0.75; 95% CI, 0.58-0.98; )Tj
/T1_5 1 Tf
0 Tc (P)Tj
/T1_4 1 Tf
-0.03 Tc 11.114 0 Td
( = 0.04\). At week 120, perfor)Tj
0 Tc 11.745 0 Td
(-)Tj
-0.03 Tc -22.859 -1.2 Td
[(mance measures had improved with ocrelizumab \(25-foot)-30 ( )]TJ
T*
[(walk test\) as well as the total volume of brain lesions on MRI.)-30 ( )]TJ
T*
(Side effects with ocrelizumab included infusion-related reac)Tj
0 Tc (-)Tj
-0.03 Tc T*
[(tions, URIs, and oral herpes. The rate of neoplasm was 2.3%)-30 ( )]TJ
T*
(in the ocrelizumab group vs 0.8% with placebo \()Tj
/T1_5 1 Tf
[(N Engl J)-29.9 ( )]TJ
0.03 Tw T*
(Med )Tj
/T1_4 1 Tf
0 Tw 2.102 0 Td
(2017;376:209-220\). The second study compared ocreli)Tj
0 Tc (-)Tj
-0.03 Tc -2.102 -1.2 Td
(zumab to interferon beta-1a in patients presenting with relaps)Tj
0 Tc (-)Tj
-0.03 Tc T*
[(ing multiple sclerosis. In two identical studies, 1,656 patients)-30 ( )]TJ
T*
[(were randomized to ocrelizumab 600 mg intravenously every)-30 ( )]TJ
T*
[(24 weeks or subcutaneous interferon beta-1a 44 mcg three)-30 ( )]TJ
T*
[(times weekly for 96 weeks. The annualized relapse rate was)-30 ( )]TJ
T*
[(lower )0.6 (with )0.5 (ocrelizumab )0.5 (in )0.6 (both )0.5 (trials )0.6 (\(0.16 )0.5 (vs. )0.6 (0.29; )]TJ
/T1_5 1 Tf
0 Tc 21.216 0 Td
(P)Tj
/T1_4 1 Tf
-0.03 Tc 0.581 0 Td
[( )0.5 (< )0.6 (0.001)-30 ( )]TJ
-21.797 -1.2 Td
(for both\). The percentage of patients with disability progres)Tj
0 Tc (-)Tj
-0.03 Tc T*
[(sion at 12 and 24 weeks was better with ocrelizumab, as were)-30 ( )]TJ
T*
[(MRI \037ndings. Serious infections were lower with ocrelizumab)-30 ( )]TJ
T*
[(compared to interferon, while neoplasms occurred in 0.5%)-30 ( )]TJ
T*
[(patients treated with ocrelizumab vs. 0.2% of those treated)-30 ( )]TJ
T*
[(with interferon beta-1a. Both the placebo-controlled trial and)-30 ( )]TJ
T*
[(the head-to-head study con\037rm the ef\037cacy of ocrelizumab.)-30 ( )]TJ
T*
[(However)111 (, further safety studies are required, especially regard)]TJ
0 Tc (-)Tj
-0.03 Tc T*
(ing the rate of neoplasm \()Tj
/T1_5 1 Tf
(N Engl J Med)Tj
/T1_4 1 Tf
[( 2017;376:221-234\).)-29.9 ( )]TJ
T*
(The FDA has granted the manufacturer of ocrelizumab Break)Tj
0 Tc (-)Tj
-0.03 Tc T*
[(through Therapy designation, which allows for an expedited)-29.9 ( )]TJ
T*
(review process.)Tj
/TT0 1 Tf
0 Tc 14 0 0 14 306 233.3608 Tm
[(FD)17.4 (A Action)]TJ
/T1_4 1 Tf
-0.03 Tc 10 0 0 10 306 221.3608 Tm
[(The FDA has approved a second cyclase-C agonist for the)-30 ( )]TJ
T*
[(treatment of chronic idiopathic constipation. Plecanatide is)-30 ( )]TJ
T*
[(a once-a-day tablet that stimulates \036uid movement in the)-30 ( )]TJ
T*
(gut and facilitates defecation. It follows linaclotide \(Linz)Tj
0 Tc (-)Tj
-0.03 Tc T*
[(ess\), which was approved in 2012 for the same indication,)-30 ( )]TJ
T*
[(although linaclotide also was approved for irritable bowel)-30 ( )]TJ
T*
[(syndrome with constipation. Plecanatide was approved on the)-29.9 ( )]TJ
T*
[(strength of two 12-week, placebo-controlled trials in 1,775)-30 ( )]TJ
T*
[(adults suffering from chronic idiopathic constipation, de\037ned)-30 ( )]TJ
T*
(by less than three defecations per week for at least the previ)Tj
0 Tc (-)Tj
-0.03 Tc T*
(ous three months, as well as other constipation-related symp)Tj
0 Tc (-)Tj
-0.03 Tc T*
[(toms. Plecanatide resulted in improved frequency of complete)-30 ( )]TJ
T*
[(spontaneous bowel movements compared to placebo as well)-30 ( )]TJ
T*
[(as improvements in stool frequency)92 (, consistency)92 (, and strain)]TJ
0 Tc (-)Tj
-0.03 Tc T*
[(ing. The most common side effect was diarrhea. Plecanatide is)-30 ( )]TJ
T*
[(marketed as T)67 (rulance. )]TJ
/CS0 cs 1 scn
/GS1 gs
/C2_0 1 Tf
0 Tc <0084>Tj
ET
endstream
endobj
17 0 obj
<>
endobj
25 0 obj
<>>>/Subtype/Form>>stream
0 0 0 1 K
3 w 4 M 0 j 0 J
/GS0 gs
q 1 0 0 1 18 754.5 cm
0 0 m
558 0 l
S
Q
endstream
endobj
26 0 obj
<>stream
HsbYPQ)N5ЪCTC&)S
7P aZRT$@@bݻۻCCo/}gJ;dz<,?&tPC#QdD9HF#QdD9HF#QdD9HF#QdD9HF#QdD9HF#QdD9HF#QdD9HF#QdD9HF#QdD9HF#QdD9HF#QdD9HF#QdD9HF#=X*-TVo͡W5
lɷa528j/K4d\zr'k|Xj<8&\݆NrqGk?eFӓ攓Oyٺ|Q蛃ƪJ\9NEu `cnH G`qmSVcjFC=c#Zhwy`ZꮭI/nnov{WbKB˶C㽖#^/Ս(4ؾ9s?}=8=+#biuR,lQAPS.3uPE3םXәuFqTgff(=Ԣ#ؾ9&>B㯌2<8>ΡW9x*rD[[X96|l4mSqrsƱ Fܠbo`6m٬x6bl9~/3<8
]ݣ㓿A4'A6o%DwFpM5QZKzsJ@a2؉~9ѭ~q9h,g~&j뎌.%Zxė<ۦ\`>z1|ل5}\v'ԃU=_/7|_J0s/ͪ/Y9a~wC3uAPH51U;pC{a0A=9NB'ārl'GZ՚%a'fc2pժ6'-bǣ̔ .SRL8mos`Nm|[X0ob9{7n=92dA_/w708wbp[ 6Hf-:[TVbSq41}>|G 7rd`zᐱEj\zW`*x$E R1'PYqYQ?&kzUsIBݻ^@rៅٗk6~߾5ix]
>prq';#z4=df 9>qcZ]d9ov擣%0q
jNΨd ]\U\tI'\jƛJNV{@'Zqu1_s>uVm#!hqd;
]f҄LicJ~0~'mck`2ds+FG YNla6X+{zϲZlv3v'iDR0[3Ozh]`ѩL.D_K~Dw( 'pUӷ=cE/PC'>f řwx}5@|&Y%vi틻{<p
C/AXe(p<{hi[Ȳ,Qq{p=TC
z֗^39zBydHnf[?tg6S=4Ѹif(ݓZne#9lʝcbc%XqX 2QWSVw~]X-#űwKWޓnl{fB¢~R,]jw'Uh1 _d)em*ll5-8s1kCe6~Q/z}<9falhS?Gx~mO=8rпČh|(pf댱/yq!qsƱv:9]16~|ҡPgg88J\9b[jN)C;#lF
w"O#* %9_(^A=5 pZxpػ:3W>XMp{Rq|Ǐ8X3G$0@Vp.Z#8'^̕#T[|^4>LU*Dqܠ*FngXxН#øӯ!Agt+lL6&Ϗ7ҘwZc8mF
f;X+դKyS9C9 Y9upxaRqdv}LJz`q=Oo#UJ%ŝcT>AWجy4zIjUypd8
1ݹ_Qg_0Ɛw4U@.@\UE
PHHAiIhd}цUBp>;ف:3w#&4_nog3V׳
!XiqZ'PgIOO,
ơQ^,'Faj+>C|[=js ThBF.uZq5ξd295$6`㦆q>eɩ,.cz[X6&9WKq
{4U1
QegNȬ:ekv'&a`tn#ǂ"J)iΆm{|ź$m*Qq!?3
ɕчwY(՞#wKSgkDRQ9Ȧ8)8^㬌!~)GݔljVREzYO̼-Jy}-iSLr*hٯfΑ_q(9¯MPf#8j=dY;W$G-H++Y}gLץD0ϔ1[\3sdf/Lđ5Vi @T6N5/6sb[ͫo/aU"hӮ^Ua
V4$i~iSn\PӪj"LUU/CNe/YhXKu:4 ^T́%̳ 4btҩ,`?{e}2^6y^ Ps\o8V]Nf_֬tV2>KFd8-E>Hɲu]*,-t(y%#w
=ǯB_!(GoD9z#QވrF7(GoD9z#QވrF7(GoD9z#QވrF7(GoD9z#QވrF7(GoD9z#QވrF7(GoD9z#QވrFo%_7Do(PQQQQQQQQQQQQQQQQQQQQQQOkW4j7.Xu塺loγ|6zZ$Gvۘ:'Թk= kEQI."zs<Ө
]H?hI`f@'ϫN8jң$Gq(!>lmTl@VڤJC3 vKb+A*B'=q/3LRLT{f2/`˅Oku!7pn7;<ޚS؉K